Skip to content Skip to footer
Subscribe Now
New Drug Designations: July 2025
INSIGHTS+

New Drug Designations: July 2025

Shots:       PharmaShots’ Designation Report offers a concise overview of the latest drug and device designations granted by major regulatory authorities, including the FDA, EMA, MHLW, Health Canada, and NMPA.    The July 2025 edition covers designations awarded to 47 drugs and 3 medical devices, comprising 23 small molecules, 9 biologics, 8 cell and gene therapies, and…
August 26, 2025

Read more

Jazz Pharmaceuticals at ASCO 2025: Robert lannone in an Illuminating Conversation with PharmaShots
VIEWPOINTS

Jazz Pharmaceuticals at ASCO 2025: Robert lannone in an Illuminating Conversation with PharmaShots

Shots:  Jazz Pharmaceuticals and partners presented seven abstracts from their oncology development program at ASCO 2025   Robert Iannone, EVP, Global Head of Research and Development, and Chief Medical Officer at Jazz Pharmaceuticals, in an engaging discussion with PharmaShots, shared insights from the P-III IMforte trial assessing Zepzelca plus atezolizumab in first-line maintenance treatment for Extensive…
August 25, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Aug 18, 2025 – Aug 22, 2025)  

This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, and Biosimilars. Check out our full report below:    HUTCHMED Completes Patient Enrolment in P-III (SANOVO) Trial of Orpathys (savolitinib) and Tagrisso (osimertinib) for EGFRm NSCLC  Read More: HUTCHMED  Akeso Reports First Patient Dosing in P-III (COMPASSION-33) Trial of Cadonilimab for…
August 22, 2025

Read more

TOP 20

Top 20 R&D Spending Biopharma Companies of 2025  

Shots:  Research and Development (R&D) serves as the driving force behind groundbreaking therapeutic innovations, laying the foundation for advancements that transform patient health and overall well-being  The global Top 20 pharmaceutical leaders spent ~$180B in 2024, with Merck & Co. contributing the most with a whopping $17.93B, followed by Johnson & Johnson ($17.23B) and Roche…
August 21, 2025

Read more

Roadblocks to Specialty Medicines Access: Colin Banas from DrFirst in Conversation with PharmaShots
VIEWPOINTS

Roadblocks to Specialty Medicines Access: Colin Banas from DrFirst in Conversation with PharmaShots 

Shots:  Fragmented workflows continue to be a major roadblock in the healthcare ecosystem, causing unnecessary delays in care delivery  Automated solutions help bridge the gaps resulting from disjointed workflows and expedite prior authorization, pharmacy routing, and patient onboarding  Colin Banas, CMO at DrFirst, joins PharmaShots in a discussion highlighting the company’s recent acquisition of Myndshft…
August 20, 2025

Read more

Drug Discovery and Innovation Programme 2025
EVENTS

Drug Discovery and Innovation Programme 2025 | Sep 25-26 |Barcelona, Spain

A B2B event designed to connect Drug Discovery Experts, Biotech Innovation, and emerging technologies. This expert-led, two-day event blends keynotes, case studies, panel discussions, and 1:1 meetings to turn research into real-world impact. For any queries, reach out to Tina Aston at ta@worldbigroup.com Related Post: Clinical Trials Operations DACH 2025 | Sep 18 | Basel,…
August 20, 2025

Read more

Load more